Europe Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Molecular, Conventional), By Infection Type (UTI, Pneumonia), By Product (Consumables, Instruments), By Type, By Country, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The Europe hospital acquired infections diagnostics market size was estimated at USD 1.48 billion in 2024 and is projected to grow at a CAGR of 1.2% from 2025 to 2030. With a significant prevalence of infections such as sepsis and surgical site infections, the demand for effective diagnostic solutions has surged. Approximately 3.4 million sepsis cases occur annually in Europe, resulting in nearly 700,000 deaths each year, underscoring the critical need for advanced diagnostic tools. The increasing incidence of bloodstream infections (BSIs) compels healthcare providers to implement robust diagnostic measures, creating a substantial market opportunity for companies specializing in hospital acquired infections (HAI) diagnostics.

Technological advancements also play a crucial role in driving growth of the Europe hospital acquired infections diagnostics industry. Continuous innovations in diagnostic technologies, particularly in molecular diagnostics and rapid testing methods, have significantly enhanced the accuracy and speed of HAI detection. These advancements enable healthcare providers to identify infections more promptly and accurately, leading to better patient outcomes. As hospitals increasingly adopt advanced diagnostic solutions, companies that innovate and enhance their diagnostic capabilities are well-positioned for growth in this competitive landscape.

In addition to technology, rising healthcare expenditure across European countries is facilitating the adoption of hospital acquired infections diagnostics. Increased investments in healthcare infrastructure and access to advanced technologies are improving the diagnostic landscape. This trend enables healthcare facilities to upgrade their diagnostic capabilities and improve patient care. Moreover, proactive government initiatives aimed at infection control and funding for research and development are pivotal in supporting market expansion. These policies create a conducive environment for the growth of diagnostic solutions, as they prioritize addressing the serious public health threat posed by hospital-acquired infections.

Furthermore, heightened patient awareness regarding the risks associated with hospital-acquired infections has amplified the demand for effective diagnostic solutions. As both patients and healthcare providers become more informed about the severe consequences of HAIs, there is a growing emphasis on timely and accurate diagnostics. This increased awareness drives healthcare providers to seek advanced diagnostic tools, further propelling market growth. In this landscape, companies that focus on developing innovative and reliable diagnostic products for HAIs stand to gain competitive advantages in the evolving European healthcare market.

Test Type Insights

Conventional tests dominated the Europe hospital acquired infections diagnostics industry and accounted for a revenue share of 54.0% in 2024. Established testing methods, such as blood cultures and urinalysis, have remained reliable and widely accepted in clinical practice due to their familiarity among healthcare professionals. These conventional diagnostic approaches have proven to be cost-effective, making them accessible to a broader range of healthcare facilities, particularly in resource-constrained settings. Their compliance with existing regulatory frameworks provides assurance, boosting confidence in their use. Conventional tests effectively detect a wide array of pathogens associated with hospital-acquired infections, integrating seamlessly into standard clinical protocols for infection control.

Molecular tests are expected to grow at the fastest CAGR over the forecast period. Molecular tests, particularly PCR-based methods, have emerged as a crucial diagnostic tool for hospital-acquired infections in Europe. Their rapid and accurate detection capabilities enable timely treatment decisions, improving patient outcomes. The increasing incidence of infectious diseases, including multidrug-resistant organisms, has driven demand for these advanced diagnostic methods, supported by government initiatives and funding.

Infection Type Insights

The urinary tract infection (UTI) segment led the market and accounted for a share of 21.6% in 2024. A significant portion of hospital-acquired UTIs are linked to urinary catheters, with studies showing that 95% of UTI episodes in intensive care units (ICUs) are catheter-related. The estimated incidence of nosocomially acquired UTIs in Europe was 3.55 episodes per 1,000 patient-days, highlighting the need for effective diagnostic solutions. Moreover, increased patient risk factors, an aging population, and a focus on infection control have intensified the demand for rapid diagnostic tools.

Pneumonia is expected to grow lucratively over the forecast period. Healthcare-associated pneumonia (HAP) was prevalent in about 1.3% of hospitalized patients in Europe, with rates reaching 8.1% in intensive care units (ICUs). A substantial number of cases were linked to intubation and mechanical ventilation, contributing to high mortality rates of 20% to 55% among ventilated patients. The rise of antimicrobial resistance (AMR) among pathogens, combined with an aging population’s susceptibility, further underscored the urgent need for effective diagnostic tools and infection control measures.

Product Insights

Consumables held the largest share of the Europe hospital acquired infections diagnostics market in 2024 and is expected to grow at a CAGR of 1.3% over the forecast period. Diagnostic consumables, such as reagents and testing kits, are essential for accurate hospital-acquired infection diagnosis. With a focus on infection control, rising infectious disease prevalence, and regulatory requirements, Europe’s hospitals consistently demand these consumables for effective management and compliance. As laboratories adopt advanced technologies, consumables demand continues, driven by the high volume of testing in ICUs and cost-effectiveness.

Instruments are expected to register rapid growth over the forecast period. Technological advancements in diagnostic tools, such as automated systems and molecular diagnostics such as PCR and next-generation sequencing, have improved HAI detection’s accuracy and efficiency. As HAIs rose, hospitals focused on infection control and regulatory compliance, requiring sophisticated instruments. The trend towards point-of-care testing and the integration of automated systems further underscored the demand for cost-effective diagnostics that enhance patient outcomes and operational efficiency.

Type Insights

Blood tests dominated the market and accounted for a share of 64.9% in 2024. Rapid identification of pathogens, particularly through blood tests and cultures, has proven critical for diagnosing HAIs swiftly. The prevalence of BSIs, coupled with rising AMR, underscores the need for effective testing methods. Innovations in blood testing technologies, regulatory guidelines, and integration into clinical protocols enhance their appeal. With a continued focus on patient safety and quality care, healthcare providers prioritize reliable blood tests to improve outcomes and minimize complications.

The urinalysis segment is projected to grow lucratively over the forecast period. UTIs accounted for 20% to 40% of hospital-acquired infections, with rates rising to 60% to 70% in urology units. High catheterization rates in these departments, reaching up to 75%, increased the demand for effective urinalysis. This cost-effective diagnostic method enables rapid diagnosis and treatment, integrates into infection control protocols, complies with regulatory standards, and enhances patient safety in healthcare settings.

Country Insights

Germany Hospital Acquired Infections Diagnostics Market Trends

The Germany hospital acquired infections diagnostics market dominated the Europe market with a revenue share of 28.3% in 2024. Germany’s advanced healthcare infrastructure, renowned for patient safety and state-of-the-art facilities, supports the need for effective diagnostics amidst the significant incidence of HAIs. Strong government investment, robust research and development, and growing awareness through organizations such as the German Sepsis Society enhance demand for advanced diagnostic solutions. Integration into clinical protocols further solidifies their vital role in managing infections and addressing AMR.

UK Hospital Acquired Infections Diagnostics Market Trends

The hospital acquired infections diagnostics market in the UK is expected to grow at the fastest rate over the forecast period. The rising incidence of hospital-acquired infections (HAIs) in the UK has driven market growth, creating a demand for effective diagnostic solutions. Technological advancements, including rapid testing methods, enhanced detection speed and accuracy. Government initiatives and increased healthcare expenditure supported research funding and public health campaigns. Growing awareness and emphasis on patient safety led to the integration of diagnostics into clinical protocols, addressing AMR effectively.

Key Europe Hospital Acquired Infections Diagnostics Company Insights

Some key companies operating in the Europe hospital acquired infections diagnostics industry include BIOMÉRIEUX; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthineers AG; among others.Major players are prioritizing strategic collaborations and technological advancements while focusing on regulatory compliance, investing in R&D to enhance product offerings and meet demand for efficient diagnostic solutions.

• bioMérieux specializes in detecting hospital-acquired infections through automated tests such as VIDAS and BacT/ALERT, improving pathogen identification and antibiotic stewardship to enhance patient outcomes and combat antimicrobial resistance.

• BD delivers innovative diagnostic solutions for detecting hospital-acquired infections, offering blood culture systems and rapid tests that enhance pathogen identification, thus improving infection management and patient safety in European hospitals.

Recent Developments

• In January 2025, BioMerieux announced its intent to pursue acquisitions with EUR 3bn- EUR 4bn available, enhancing its core segments within the diagnostics market.

Europe Hospital Acquired Infections Diagnostics Market Report Scope

Europe Hospital Acquired Infections Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Europe hospital acquired infections diagnostics market report based on test type, infection type, product, type, and region:

• Test Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Molecular

  • Conventional

• Infection Type Outlook (Revenue, USD Million, 2018 - 2030)

  • UTI

  • Pneumonia

  • Surgical Site Infection

  • Blood Stream Infections

  • Others

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

  • Instruments

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood Tests

  • Urinalysis

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Russia

  • Netherlands